EUVIMEDEUVIMED entdecken
Crossref

Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia

Chih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, Elane Coustan-Smith, Gang Wu, Chao-Neng Cheng, Meng-Yao Lu, Kai-Hsin Lin, Kang-Hsi Wu, Shu-Huey Chen, Fang-Liang Huang, Hsiu-Hao Chang und 18 weitere

Cancer · 2023-03 · 129 (5) · 790-802

DOI: 10.1002/cncr.34606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 20.12.2022. Verfasst von Chih-Hsiang Yu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study analyzed data from two consecutive protocols for children newly diagnosed with acute lymphoblastic leukemia (ALL) to determine the clinical impact of minimal/measurable residual disease (MRD) and recently identified tumor genetic subtypes.

Methods

Genetic subtypes were determined by sequential approaches including DNA indexing, reverse transcriptase–polymerase chain reaction, multiplex ligation‐dependent probe amplification, and RNA‐sequencing. MRD was assessed by flow cytometry. The Taiwan Pediatric Oncology Group TPOG‐ALL‐2013 study enrolled patients who received MRD‐directed therapy.

Results

The 5‐year event‐free survival (EFS) and overall survival rates in the 2013 cohort were 77.8% and 86.9% compared to those of the 2002 cohort, which were 62.4% and 76.5%. Among patients treated with MRD‐guided therapy, those with ETV6‐RUNX1 fusion and high hyperdiploidy had the highest 5‐year EFS (91.4% and 89.6%, respectively). The addition of dasatinib improved outcomes in patients with BCR‐ABL1 ALL. Recently identified subtypes like DUX4 ‐rearranged, ZNF384 ‐rearranged, MEF2D ‐rearranged, and PAX5 alt subtypes were frequently positive for MRD after remission induction, and these patients consequently received intensified chemotherapy. Treatment intensification according to the MRD improved the outcomes of patients presenting DUX4 rearrangements. In high‐risk or very‐high‐risk subtypes, the TPOG‐ALL‐2013 regimen did not confer significant improvements compared to TPOG‐ALL‐2002, and the outcomes of BCR‐ABL1 ‐like, MEF2D ‐rearranged, and KMT2A ‐rearranged ALL subtypes (in addition to those of T‐cell ALL) were not sufficiently good. Novel agents or approaches are needed to improve the outcomes for these patients.

Conclusions

The TPOG‐ALL‐2013 study yielded outcomes superior to those of patients treated in the preceding TPOG‐ALL‐2002 study. This study provides important data to inform the design of future clinical trials in Taiwan. Plain language summary MRD‐directed therapy improved the outcomes for pediatric ALL, especially standard‐risk patients. Genomic analyses and MRD might be used together for risk‐directed therapy of childhood ALL. Our work provides important data to inform the design of future clinical trials in Taiwan

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaChildHumansNeoplasm, ResidualPrognosisDasatinibRemission Induction

Stichwörter der Autor:innen

Taiwan Pediatric Oncology Groupchemotherapy regimenchildhood acute lymphoblastic leukemiagenetic subtypesminimal residual disease

Substanzen

Dasatinib

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Institute of Statistical Science Academia Sinica, Taipei, Taiwan.
  • Department of Pediatrics, National Taiwan University Children's Hospital, Taipei, Taiwan.
  • Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Childhood Cancer Foundation, Taipei, Taiwan.
  • Department of Pediatrics, Yong, Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Shu-Wei Chou, Ching-Hon Pui, Yung-Li Yang

Förderung

  • NIH HHS

Zitieren

APA

Yu, C. H., Jou, S. T., Su, Y. H., Coustan-Smith, E., Wu, G., Cheng, C. N., Lu, M. Y., Lin, K. H., Wu, K. H., Chen, S. H., Huang, F. L., Chang, H. H., Wang, J. L., Yen, H. J., Li, M. J., Chou, S. W., Ho, W. L., Liu, Y. L., Chang, C. C., …, & Yang, Y. L. (2023). Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia. Cancer, 129(5), 790-802. https://doi.org/10.1002/cncr.34606

Vancouver

Yu CH, Jou ST, Su YH, Coustan-Smith E, Wu G, Cheng CN, et al. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia. Cancer. 2023;129(5):790-802. doi:10.1002/cncr.34606

BibTeX
@article{Yu2023,
  author = {Yu, Chih-Hsiang and Jou, Shiann-Tarng and Su, Ying-Hui and Coustan-Smith, Elane and Wu, Gang and Cheng, Chao-Neng and Lu, Meng-Yao and Lin, Kai-Hsin and Wu, Kang-Hsi and Chen, Shu-Huey and Huang, Fang-Liang and Chang, Hsiu-Hao and Wang, Jinn-Li and Yen, Hsiu-Ju and Li, Meng-Ju and Chou, Shu-Wei and Ho, Wan-Ling and Liu, Yen-Lin and Chang, Chia-Ching and Lin, Ze-Shiang and Lin, Chien-Yu and Chen, Hsuan-Yu and Ni, Yu-Ling and Lin, Dong-Tsamn and Lin, Shu-Wha and Yang, Jun J and Ni, Yen-Hsuan and Pui, Ching-Hon and Yu, Sung-Liang and Yang, Yung-Li},
  title = {Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {5},
  pages = {790--802},
  doi = {10.1002/cncr.34606}
}
Kostenlos starten →